Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Parcel Service
UPS
|
+$428M |
| 2 |
DexCom
DXCM
|
+$384M |
| 3 |
WIX.com
WIX
|
+$359M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$254M |
| 5 |
Caesars Entertainment
CZR
|
+$246M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.14B |
| 2 |
Microchip Technology
MCHP
|
+$535M |
| 3 |
Merck
MRK
|
+$512M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$444M |
| 5 |
Illumina
ILMN
|
+$413M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.59% |
| 2 | Healthcare | 18.35% |
| 3 | Consumer Discretionary | 11.3% |
| 4 | Financials | 10.45% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Enovis
ENOV
$1.74B
| – | – |
-29,389
| Closed | -$2.22M |
|
1627
Energizer
ENR
$1.47B
| – | – |
-68,618
| Closed | -$3.26M |
|
1628
FIVE9
FIVN
$2.08B
| – | – |
-58,688
| Closed | -$9.18M |
|
1629
Frontline
FRO
$8.71B
| – | – |
-109,665
| Closed | -$802K |
|
1630
GoodRx Holdings
GDRX
$1.09B
| – | – |
-82,714
| Closed | -$3.23M |
|
1631
GSK
GSK
$107B
| – | – |
-6,938
| Closed | -$310K |
|
1632
Hess Midstream
HESM
$5.19B
| – | – |
-95,238
| Closed | -$2.13M |
|
1633
Hovnanian Enterprises
HOV
$779M
| – | – |
-2,330
| Closed | -$246K |
|
|
IGMS
1634
DELISTED
IGM Biosciences
IGMS
| – | – |
-268,933
| Closed | -$20.6M |
|
1635
Independent Bank
INDB
$4.04B
| – | – |
-157,625
| Closed | -$13.3M |
|
1636
Ionis Pharmaceuticals
IONS
$8.93B
| – | – |
-76,644
| Closed | -$3.45M |
|
1637
Iovance Biotherapeutics
IOVA
$2.04B
| – | – |
-78,211
| Closed | -$2.48M |
|
|
JWN
1638
DELISTED
Nordstrom
JWN
| – | – |
-57,181
| Closed | -$2.17M |
|
1639
Coca-Cola Femsa
KOF
$22.5B
| – | – |
-527,195
| Closed | -$24.3M |
|
1640
Kymera Therapeutics
KYMR
$8.66B
| – | – |
-397,708
| Closed | -$15.5M |
|
1641
Pulmonx
LUNG
$52.8M
| – | – |
-152,082
| Closed | -$6.96M |
|
1642
MGP Ingredients
MGPI
$403M
| – | – |
-3,615
| Closed | -$214K |
|
1643
Middleby
MIDD
$6.01B
| – | – |
-7,730
| Closed | -$1.28M |
|
1644
Miller Industries
MLR
$577M
| – | – |
-5,014
| Closed | -$232K |
|
1645
MP Materials
MP
$6.78B
| – | – |
-96,587
| Closed | -$3.47M |
|
1646
Neogen
NEOG
$2.05B
| – | – |
-61,488
| Closed | -$2.73M |
|
1647
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-3,922
| Closed | -$1.18M |
|
1648
Nutanix
NTNX
$16.1B
| – | – |
-141,061
| Closed | -$3.75M |
|
1649
Nu Skin
NUS
$257M
| – | – |
-17,500
| Closed | -$926K |
|
1650
OGE Energy
OGE
$9.86B
| – | – |
-14,262
| Closed | -$462K |
|
Similar funds
Janus Henderson Group's Q2 2021 Portfolio in Review
As of Q2 2021, Janus Henderson Group held 1,725 positions worth $234B, up 6.7% from $219B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Janus Henderson Group's Q2 2021 filing shows 172 new, 741 increased, 667 reduced and 123 closed positions. Its largest new stake was Centessa Pharmaceuticals: 5,680,933 shares worth $120M. The largest sale was Apple, an estimated $1.14B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2021 buy was Centessa Pharmaceuticals: 5,680,933 shares worth $120M.
- Janus Henderson Group added most to United Parcel Service in Q2 2021, an estimated $428M increase.
- Janus Henderson Group's biggest Q2 2021 reduction was Apple, cutting an estimated $1.14B.
- Janus Henderson Group fully exited PRA Health Sciences, Inc. in Q2 2021, selling an estimated $368M.
- Janus Henderson Group's ten largest holdings make up 23% of its $234B portfolio in Q2 2021.
- Janus Henderson Group opened 172 new positions and closed 123 in Q2 2021.
- Janus Henderson Group's portfolio value rose 6.7% quarter-over-quarter to $234B.
Based on Janus Henderson Group's 13F filing for Q2 2021, filed 16 Aug 2021.